4.7 Article

Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity

Journal

MOLECULAR THERAPY
Volume 25, Issue 8, Pages 1900-1916

Publisher

CELL PRESS
DOI: 10.1016/j.ymthe.2017.04.022

Keywords

-

Funding

  1. Canadian Institutes of Health Research grant [MOP130401]
  2. Prostate Cancer Research Foundation of Canada grant [D2013-23]
  3. Fondazione Cenci Bolognetti
  4. NIH [1R21CA192185- 01]
  5. Italian Association for Cancer Research [AIRC-AG16901]
  6. Cancer Research UK [C20953/A18644]
  7. BBSRC [BB/L01923X/1]
  8. Peter Quinlan McGill Postdoctoral Fellowship
  9. Canadian Cancer Society Travel Award grant
  10. Fond de la Recherche Sante Quebec (FRSQ) Fellowship award
  11. Biotechnology and Biological Sciences Research Council [BB/L01923X/1] Funding Source: researchfish
  12. Cancer Research UK [18644] Funding Source: researchfish
  13. BBSRC [BB/L01923X/1] Funding Source: UKRI

Ask authors/readers for more resources

Oncolytic viruses (OVs) offer a promising therapeutic approach to treat multiple types of cancer. In this study, we show that the manipulation of the antioxidant network via transcription factor Nrf2 augments vesicular stomatitis virus Delta 51 (VSV Delta 51) replication and sensitizes cancer cells to viral oncolysis. Activation of Nrf2 signaling by the antioxidant compound sulforaphane (SFN) leads to enhanced VSV Delta 51 spread in OV-resistant cancer cells and improves the therapeutic outcome in different murine syngeneic and xenograft tumor models. Chemoresistant A549 lung cancer cells that display constitutive dominant hyperactivation of Nrf2 signaling are particularly vulnerable to VSV Delta 51 oncolysis. Mechanistically, enhanced Nrf2 signaling stimulated viral replication in cancer cells and disrupted the type I IFN response via increased autophagy. This study reveals a previously unappreciated role for Nrf2 in the regulation of autophagy and the innate antiviral response that complements the therapeutic potential of VSV-directed oncolysis against multiple types of OV-resistant or chemoresistant cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available